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Abstract
Background: Accumulating evidence consistently demonstrates that blood transfusion in cardiac surgery is related
to decreased short- and long-term survival. We aimed to evaluate periprocedural blood loss and transfusion rates in
elective, isolated total arterial coronary artery bypass grafting (CABG) using exclusively skeletonized bilateral internal
mammary arteries (IMAs).
Methods: We identified 1011 consecutive patients with coronary artery disease who underwent CABG between 1/
2007 and 12/2014. Of them, 595 patients who presented preoperative hemoglobin levels >9md/dl and underwent
elective, isolated CABG for multi-vessel coronary artery disease were included in the study population. 419 patients
(70.4%) received total arterial CABG using skeletonized bilateral IMAs, in 176 patients (29.6%) mixed CABG (single
IMA & saphenous vein) was performed. Propensity score adjustment using 16 variables was applied to control for
treatment effect.
Results: In patients undergoing total arterial CABG, heterologous blood transfusion could be avoided in 87.8% of all
cases. Propensity score adjusted results showed a significantly lower incidence of erythrocyte concentrate transfusion
in patients undergoing total arterial CABG compared to mixed CABG (odds ratio 2.74, 95% confidence interval 1.38–
5.43, P = 0.004). There were no statistically significant differences in the rates of thrombocyte concentrate (P = 0.39) and
fresh frozen plasma transfusions (P = 0.07).
Conclusions: In this study, patients who underwent elective, isolated total arterial CABG using exclusively skeletonized
bilateral IMAs showed reduced transfusion rates of erythrocyte concentrates compared to mixed CABG using a combination
of single IMA and saphenous vein grafts. No evidence for a higher incidence of complications was found with a total arterial
approach.
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Introduction
Blood loss is still one of the most frequent and feared
complications in cardiac surgery leading to the con-
sumption of a significant proportion of all blood prod-
ucts worldwide [1]. While blood transfusions are crucial
in salvage procedures, they come with an increased risk
of adverse effects such as the formation of alloantibodies
and hemolytic transfusion reactions, allergic transfusion
reactions, transfusion-associated circulatory overload,
transfusion-related acute lung injury or the transmission
of infections and transfusion-related immune modulation
[2–5]. Accumulating evidence therefore demonstrates that
a liberal strategy of red-cell transfusion in cardiac surgery
shows no apparent benefits but is rather related to de-
creased short- and long-term survival [6–8].
Even the transfusion of a single blood unit has been
shown to increase mortality and the length of hospital stay
after CABG [9]. Results from both the Transfusion Re-
quirements After Cardiac Surgery (TRACS) trial and the
TRICS III Trial showed no inferiority of a restrictive trans-
fusion strategy in cardiac surgery [10, 11] with respect to a
composite outcome of death, stroke, myocardial infarction
and acute renal failure. Furthermore, the Transfusion
Indication Threshold Reduction (TITRe2) trial found no
increase in the primary outcome of serious infections and/
or ischemic events with a restrictive strategy [12].
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According to numerous retrospective studies, total ar-
terial CABG using bilateral internal mammary arteries
(BIMA) is associated with improved long-term graft pa-
tency, long-term survival and reduced risk for cardiac
events and cardiac death compared to mixed CABG using
single internal mammary artery (SIMA) and saphenous
veins (SV) [13–15]. While the first randomized trial on
CABG survival at 10 years between BIMA and SIMA, the
Arterial Revascularization Trial (ART), still awaits its out-
come data, the analysis of clinical and safety outcomes
after 5 years shows no significant differences in the rates
of death, stroke or myocardial infarction between the bi-
lateral- and single-arterial graft groups [16]. However,
until now a total arterial approach is still chosen in less
than 10% of all CABG procedures performed in Europe
[17]. In consideration of the high SV graft failure rate of
up to 30% between 12 and 18months (as reported in the
PREVENT IV trial [18]), we perform total arterial CABG
with IMAs as a preferential treatment in all patients
assigned for coronary revascularization in our center.
While the goal of a bloodless intervention has brought up
numerous blood-saving procedures and systems, the ideal
surgical technique has yet not been addressed appropri-
ately. Since there are currently no prospective trials exam-
ining blood product utilization in patients undergoing total
arterial revascularization, the objective of this study was to
evaluate transfusion rates in total arterial CABG using
exclusively skeletonized BIMA compared to mixed CABG
using a composition of SIMA and SV conduits.
Patients and methods
After obtaining approval by the local research ethics com-
mittee (Project-ID: 2017–00929), we reviewed a single-
center database containing a total of 1011 adult CABG
procedures performed between January 2007 and Decem-
ber 2014 at the Cardiac Center Bodensee, Switzerland.
Data were collected retrospectively.
Patient selection
From the starting population of 1011 patients we excluded
all patients who were not amenable to an all-arterial ap-
proach, such as patients undergoing salvage procedures
(N = 46) or total venous CABG using exclusively SV grafts
(N = 29). We excluded all patients who were prone to ex-
perience increased blood loss due to concomitant proce-
dures (N = 272) or who were prone to receive blood
products due to low preoperative hemoglobin levels (N =
29). We excluded patients with single-vessel coronary ar-
tery disease (N = 40) since these patients were commonly
only grafted with a single conduit. The study population
included only patients with multi-vessel coronary artery
disease who underwent elective, isolated CABG proce-
dures. Full exclusion criteria and study group breakdown
are shown in Fig. 1.
Within our study population, patients were attributed to
two groups. The group undergoing total arterial CABG in-
cludes patients who were revascularized using exclusively
BIMA conduits (N = 419) and the mixed CABG group in-
cludes patients who received a composition of SIMA and
SV conduits (N = 176).
Study endpoints
Primary endpoints were defined as periprocedural trans-
fusion rates of packed red blood cells (erythrocyte con-
centrates, EC), thrombocyte concentrates (TC) and fresh
frozen plasma (FFP) between the two groups during pri-
mary hospitalization. Periprocedural transfusion was de-
fined as the transfusion of any of the above-mentioned
blood products between the beginning of the cardiac
surgery and the discharge from hospital. As secondary
endpoints we assessed early outcomes, including 30-day
all-cause mortality, stroke, perioperative myocardial in-
farction, deep sternal wound infection requiring surgical
revision and surgical revision of hemorrhage.
Baseline data of preoperative anticoagulation in con-
sideration of plasma half-life were listed in five groups:
Acetylsalicylic acid (discontinuation time: 7d), ADP re-
ceptor inhibitors (discontinuation time: 7d (Prasugrel),
5d (Clopidogrel and Ticagrelor)), Vitamin K antagonists
(discontinuation time: 7d (Phenprocoumon), 3d (Aceno-
coumarol)), Factor Xa inhibitors (discontinuation time:
2-7d (depending on renal and hepatic function) and
GPIIb/IIIa inhibitors (discontinuation time: 6 h).
Surgical technique
Median sternotomy was performed in all patients. All IMAs
were skeletonized from the subclavian artery to the bifur-
cation and either harvested as free conduits for composite
grafting or used as in situ grafts. Double clipping was per-
formed on the side branches and topical papaverine and
intraluminal heparinized solution of Ringer’s Lactate was
applied for graft viability and spasm prophylaxis. SV grafts
were harvested by an open method using double clipping.
All procedures were performed on a conventional cardio-
pulmonary bypass using single aortic cross-clamping with
cold blood cardioplegia. Moderate systemic hypothermia
was induced. The grafting strategy and the use of total
arterial or mixed CABG primarily depended on IMA graft
quality and length. Several different graft configurations
were used depending on the anatomy, configuration of cor-
onary lesions, heart volume and total graft length needed.
For blood saving we used retrograde autologous priming
on the cardiopulmonary bypass, reducing the standard
priming volume to approximately 400ml. Furthermore,
the Cell Saver autotransfusion system was applied in redo-
cases and in patients under dual antiplatelet therapy.
Intraoperatively, all patients received tranexamic acid in a
continuous scheme. Monofilament suture lines were
Werner et al. Journal of Cardiothoracic Surgery           (2020) 15:23 Page 2 of 9
used for all cannulation sites and all anastomoses. In
all patients, CABG and the control of hemostasis was
performed by the attending surgeon (A.K.) or under
his supervision. No sealant at all was used for
hemostasis and clipping was preferred for bleeding
control whenever possible.
As recommended by the current clinical practice guide-
lines for blood transfusion, we followed a restrictive transfu-
sion strategy perioperatively using a hemoglobin threshold
of 7 g/dl in patients with a hemodynamically stable anemia.
After cardiopulmonary bypass, indication for platelet trans-
fusion was driven by clinical criteria such as substantial
Fig. 1 Flow diagram showing exclusion criteria and study group breakdown. AVR: aortic valve replacement, ASD: atrial septal defect, CEA: carotid
endarterectomy, MVR: mitral valve reconstruction
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microvascular bleeding and/or excessive postoperative
anemia in combination with a low platelet count < 50*109/l
and/or antiplatelet therapy. Indication for FFP transfusion
was given for correction of substantial microvascular bleed-
ing, especially in the presence of coagulation factor deficien-
cies. The transfusion strategy was identical in all patients
and did not depend on grafting strategy.
Statistical analysis
Continuous variables are reported as mean ± standard
deviation and were compared using the unpaired t-test
for normal distributions and Mann-Whitney U test for
non-normal distributions. Categorical variables are
expressed as frequencies and percentages and were com-
pared using Chi2-Pearson-test.
Binary logistic regression was used to identify odds
ratios of crude comparisons. To minimize the effect of
potential confounding due to baseline dissimilarities or
treatment selection, a propensity score adjustment was
performed. Using binary logistic regression, a propensity
score was generated for each patient with the treatment
group as the dependent variable and sixteen independent
variables (covariates). A logistic model was applied for
the estimation of the propensity score. Covariates that
were assumed to influence perioperative blood loss were
chosen without previous knowledge of the clinical out-
comes (outcome blinded). Covariates included the base-
line clinical variables age, sex, era, arterial hypertension,
diabetes, dyslipidemia, obesity, preoperative left ven-
tricular ejection fraction (LVEF), perioperative anticoa-
gulation (in five groups), number of distal anastomoses,
preoperative hemoglobin levels, aortic cross-clamp time.
Propensity adjustment was performed by logistic regres-
sion with the incidence of transfusion as the dependent
variable and the treatment group and the propensity
score on a logit scale as the independent variables. The
validity of the logistic regression was assessed using the
Hosmer-Lemeshow test. All reported p values are two-
sided and a value of p < 0.05 was considered statistically
significant. Statistical analysis was performed in IBM
SPSS Statistics Version 22 (SPSS Inc., Chicago, IL).
Results
Baseline profiles
The baseline clinical profile of the total arterial and
mixed CABG groups as well as the entire cohort is pre-
sented in Table 1. The two groups showed similar distri-
bution of sex, age, hypertension, obesity, dyslipidemia,
crossclamp time and anticoagulation scheme. Preopera-
tive hemoglobin levels were not significantly different
between the two groups. Patients undergoing mixed
CABG showed lower preoperative LVEF and were more
likely to be diabetic. Of all patients, 91.9% (91.4% in the
total arterial and 93.2% in the mixed group) were under
active anticoagulation or antiaggregation during cardiac
surgery. The anticoagulation and antiaggregation regi-
men mainly comprised acetylsalicylic acid and ADP
receptor inhibitors (83.7 and 20.3% of all patients,
respectively).
Surgical details
The mean numbers of distal anastomoses were 3.1 ± 0.9
in the total arterial CABG group and 3.9 ± 0.9 in the
mixed CABG group (p < 0.001). In patients receiving a
SV graft, sequential grafting was performed in 68.6% of
all patients, with 2 distal anastomoses in 41.8%, 3 distal
anastomoses in 20.6% and 4 distal anastomoses in 6.2%
of all patients. In 31.4% of the patients receiving a SV
graft, only one distal anastomosis was made. Composite
grafting was performed significantly more often in pa-
tients undergoing total arterial CABG with a total of 200
cases (47.7%), compared to mixed CABG where compos-
ite grafting was performed in 8 cases (4.5%, p < 0.001).
In total arterial CABG, one IMA was used as an in-situ
graft in 124 patients (29.6%) and both IMAs were used
as in-situ grafts in 286 patients (68.3%).
Similar aortic crossclamp times were found in the total
arterial and the mixed CABG group (79.0 ± 28.9 min
and 76.2 ± 25.2 min, respectively, P = 0.25). However, no
significant difference in the aortic crossclamp time was
found between patients where erythrocyte concentrates
were transfused and patients who did not require EC
transfusion (80.2 + 25.4 min and 77.9 + 28.2 min, respect-
ively, p = 0.45).
Clinical outcomes
Crude comparisons of early outcomes and blood loss are
presented in Table 2. A significant reduction in the need
for surgical revision of hemorrhage (0.5% vs. 2.8%, p =
0.015) was found in the total arterial CABG group com-
pared to the mixed CABG group.
In 12.2% of all patients undergoing total arterial
CABG, EC units were transfused perioperatively. Mixed
CABG was associated with a significantly higher inci-
dence of EC transfusion (30.1%, p < 0.001). In crude
comparison, the mixed CABG group showed higher inci-
dence of TC transfusion and FFP transfusion than the
total arterial CABG group (p = 0.006 and p = 0.003, re-
spectively). The quantity of transfused EC units, TC
units and FFP units was significantly lower in total arter-
ial CABG (2 vs. 5 EC-units at the 95th percentile, p <
0.001; 0 vs. 2 TC-units at the 97th percentile, p = 0.007;
and 0 vs. 3 FFP-units at the 97th percentile, p = 0.003)
(Fig. 2).
Propensity score adjusted comparisons are shown in
Table 3 and Fig. 3. Propensity score adjustment showed
a Hosmer-Lemeshow test p value of 0.679. After adjust-
ment, there was a significantly lower incidence of EC
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transfusion in patients undergoing total arterial CABG
compared to mixed CABG (odds ratio [OR] 2.74, 95%
confidence interval [CI] 1.38–5.43, p = 0.004). However,
there was no statistically significant difference in the in-
cidence of TC transfusions (p = 0.39) and FFP transfu-
sions (p = 0.07), all-cause 30-day mortality (p = 0.99),
postoperative stroke (p = 0.92), sternal infection (p =
0.12) and surgical revision of hemorrhage (p = 0.68) in
the adjusted samples.
Examining the effect of single risk factors, lower pre-
operative hemoglobin levels (p < 0.001), older age (p <
0.001), female sex (p < 0.001) and arterial hypertension
(p = 0.016) were associated with increased EC transfu-
sion rates, whereas no such association was found in dia-
betes (p = 0.28) and obesity (BMI > 30 kg/cm2, p = 0.21).
Patients receiving four or more distal anastomoses did
not show increased EC transfusion rates compared to
patients in which three or less distal anastomoses were
required (p = 0.052). Active medical treatment with Vita-
min K antagonists and ADP receptor inhibitors formed
risk factors for increased EC transfusion rates (p = 0.001
and p = 0.018, respectively). No significant association
with greater EC transfusion rates was found with Acetyl-
salicylic acid (p = 0.76), Factor Xa inhibitors (p = 0.13)
and GPIIb/IIIa inhibitors (p = 0.81).
Discussion
This present single-center study compares two different
CABG strategies: total arterial CABG using BIMA and
mixed CABG using a composition of SIMA and SV con-
duits, in relation to periprocedural blood loss. The main
finding after propensity score adjustment was that pa-
tients with multi-vessel coronary artery disease who
underwent elective, isolated total arterial CABG using
exclusively skeletonized BIMA demonstrated a signifi-
cantly reduced incidence of EC transfusion.
Table 1 Baseline clinical profile of the entire cohort
Variable Entire cohort
N = 595
Total arterial CABG
N = 419 (70.4%)
Mixed CABG
N = 176 (29.6%)
p value
Male 501 (84.2%) 360 (85.9%) 141 (80.1%) 0.08
Age (y) 66.1 ± 9.5 66.0 ± 9.5 66.5 ± 9.5 0.55
< 60 139 (23.4%) 100 (23.9%) 39 (22.2%) –
60–69 230 (38.7%) 167 (39.9%) 63 (35.8%) –
70–79 186 (31.3%) 124 (29.6%) 62 (35.2%) –
≥ 80 40 (6.7%) 28 (6.7%) 12 (6.8%) –
Diabetes 162 (27.2%) 105 (25.1%) 57 (32.4%) 0.016
Hypertension 427 (71.8%) 299 (71.4%) 128 (72.7%) 0.07
Obesity (BMI > 30 kg/cm2) 197 (33.1%) 139 (33.2%) 58 (32.9%) 0.58
Dyslipidemia 385 (64.7%) 275 (65.6%) 110 (62.5%) 0.67
Preoperative hemoglobin 13.2 ± 1.8 13.3 ± 1.7 13.0 ± 1.8 0.07
Preoperative LVEF 52.0 ± 13.1 54.5 ± 11.8 45.7 ± 14.2 < 0.001
Anticoagulation and antiaggregation
No anticoagulation or antiaggregation 48 (8.1%) 36 (8.6%) 12 (6.8%) 0.60
Acetylsalicylic acid 498 (83.7%) 359 (85.7%) 139 (79.0%) 0.61
ADP receptor inhibitors 121 (20.3%) 87 (20.8%) 34 (19.3%) 0.96
Vitamin K antagonists 9 (1.5%) 5 (1.2%) 4 (2.3%) 0.28
Factor Xa inhibitors 12 (2.0%) 6 (1.4%) 6 (3.4%) 0.09
GPIIb/IIIa inhibitors 26 (4.4%) 19 (4.5%) 7 (4.0%) 0.87
No. of distal anastomoses 3.4 ± 1.0 3.1 ± 0.9 3.9 ± 0.9 < 0.001
2 127 (21.3%) 117 (27.9%) 10 (5.7%) –
3 221 (37.1%) 170 (40.6%) 51 (29.0%) –
4 168 (28.2%) 96 (22.9%) 72 (40.9%) –
5 70 (11.8%) 34 (8.1%) 36 (20.5%) –
6 9 (1.5%) 2 (0.5%) 7 (4.0%) –
Crossclamp time (min) 78.2 ± 27.8 79.0 ± 28.9 76.2 ± 25.2 0.25
Composite grafting 208 (35.0%) 200 (47.7%) 8 (4.5%) < 0.001
LVEF left ventricular ejection fraction
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Our data from baseline profiles indicate a mostly
homogenous distribution of cardiovascular risk factors,
anticoagulant and antiaggregant therapy, preoperative
hemoglobin levels and crossclamp times between the two
groups. The number of distal anastomoses was significantly
lower in total arterial CABG compared to mixed CABG
(3.1 ± 0.9 and 3.9 ± 0.9, respectively). However, complete
revascularization was the first priority in our grafting strat-
egy and a hybrid procedure with single percutaneous
coronary intervention to the right coronary artery was per-
formed, if the goal of a complete revascularization could
not be achieved by BIMA.
After propensity score adjustment, our results demon-
strate a 2.7-fold increased incidence of blood transfusions
in mixed compared to total arterial CABG. Moreover, a
significant reduction of the quantities of transfused EC
units was found with the total arterial approach. No differ-
ence in the incidence of TC- and FFP-transfusion was
found in the propensity-adjusted analysis.
In order to explain these findings, we identified two
main mechanisms that lead to blood loss after CABG
surgery: First, there are cardiac causes, such as bleeding
from cannulation sites, bleeding from proximal or distal
anastomoses or bleeding from the bypass conduit itself,
e.g. after inadequate clipping of side branches. These
causes usually result in substantial hemorrhage and
require urgent surgical revision. Second, there are non-
cardiac causes, such as bleeding of the sternotomy,
bleeding of the IMA-bed or bleeding into the subcutane-
ous tissue after SV harvesting. Contrary to the cardiac
causes, these causes produce a diffuse, gradually progres-
sing blood loss.
Table 2 Early outcomes and variables of perioperative blood loss of the unadjusted cohort
Variable Entire cohort
N = 595
Total arterial CABG
N = 419 (70.4%)
Mixed CABG
N = 176 (29.6%)
p value
Early postoperative outcomes
All-cause 30-day mortality 3 (0.5%) 1 (0.2%) 2 (1.1%) 0.16
Postoperative MI 1 (0.2%) 1 (0.2%) 0 (0.0%) 0.52
Postoperative stroke 8 (1.3%) 6 (1.4%) 2 (1.1%) 0.78
Sternal infection 3 (0.5%) 2 (0.5%) 1 (0.6%) 0.89
Return for bleeding 7 (1.2%) 2 (0.5%) 5 (2.8%) 0.015
Incidence of transfusions
EC-transfusion 104 (17.5%) 51 (12.2%) 53 (30.1%) < 0.001
TC-transfusion 15 (2.5%) 6 (1.4%) 9 (5.1%) 0.006
FFP-transfusion 23 (3.9%) 10 (2.4%) 13 (7.4%) 0.003
Transfused units
EC-units (95th percentile) 3 2 5 < 0.001
TC-units (97th percentile) 0 0 2 0.007
FFP-units (97th percentile) 2 0 3 0.003
EC erythrocyte concentrate, FFP fresh frozen plasma, MI myocardial infarction, TC thrombocyte concentrate
Fig. 2 Histiogram depicting periprocedural transfusion rates of erythrocyte concentrates (EC), thrombocyte concentrates (TC) and fresh frozen
plasma (FFP) during primary hospitalization. The data represent the unadjusted study population (N = 595, total arterial CABG: N = 419, mixed
CABG: N = 176)
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In our study population, no significant difference in
the incidence of surgical revision of hemorrhage was
present between the two groups after propensity score
adjustment. We therefore presume that the reduced
rates of EC transfusion in total arterial CABG originate
from a reduction in non-cardiac causes of blood loss. It
has been demonstrated in various studies that BIMA
harvesting results in a deteriorated pre- and retrosternal
microcirculation [19–21]. After BIMA harvesting, sternal
bone perfusion is merely based on the blood flow from
intercostal arteries. Consequently, decreased sternal
blood flow in total arterial CABG using BIMA may lead
to reduced bleeding of the sternotomy. Furthermore, in
contrary to every other graft type, no second or ex-
tended skin incision is required for IMA graft harvesting.
While SV harvesting was always performed using the
open technique in this study, we believe that endocopic
SV harvesting would not have attenuated the blood con-
sumption in the mixed CABG group. In fact, previous
studies comparing endoscopic SV harvesting to open SV
harvesting have demonstrated no significant difference
in the incidence of red blood cell transfusions [22] or
hematoma formation [23]. We are convinced that also
the surgeon’s experience and meticulousness is a crucial
factor for perioperative bleeding and the consumption of
blood products. Since in this present study, all opera-
tions were performed by or under supervision of the at-
tending surgeon (A.K.), the bias from different surgeons
is minimized.
Contrary to previous findings by Karthik et al. [24],
the number of distal anastomoses did not show an inde-
pendent association with blood transfusions in our study
population. Patients receiving four or more distal anasto-
moses did not show a higher incidence of blood transfu-
sion compared to patients receiving three or less distal
anastomoses. Moreover, while Karthik et al. [25] de-
scribed an increased risk for excessive bleeding with pre-
operative use of Acetylsalicylic acid, no significant
association with greater transfusion rates was found in
our population. In accordance to previous studies, where
the use of ADP receptor inhibitors in addition to Acetyl-
salicylic acid has been an independent predictor of EC
transfusions and re-operation for bleeding, active med-
ical treatment with ADP receptor inhibitors was as
associated with increased EC transfusion rates in our
univariable analysis [26, 27].
An argument that is often used against the utilisation
of BIMA conduits in total arterial CABG is its
Table 3 Crude comparison and propensity score adjustment of blood consumption and early outcomes of patients undergoing
mixed CABG (N = 176) compared to total arterial CABG (N = 419)
Variable Odds ratio 95% CI (lower) 95% CI (upper) p value
EC transfusion
Crude comparison 3.25 2.10 5.00 < 0.001
Propensity score adjusted 2.74 1.38 5.43 0.004
TC transfusion
Crude comparison 3.83 1.34 10.93 0.012
Propensity score adjusted 2.36 0.34 16.65 0.39
FFP transfusion
Crude comparison 3.37 1.45 7.84 0.005
Propensity score adjusted 3.59 0.90 14.34 0.07
All-cause 30-day mortality
Crude comparison 4.81 0.43 53.33 0.20
Propensity score adjusted 0.92 0.06 13.55 0.99
Postoperative stroke
Crude comparison 0.79 0.16 3.96 0.78
Propensity score adjusted 1.14 0.10 12.52 0.92
Sternal infection
Crude comparison 1.19 0.11 13.23 0.89
Propensity score adjusted 0.05 0.01 2.24 0.12
Return for bleeding
Crude comparison 6.10 1.17 31.73 0.032
Propensity score adjusted 0.50 0.02 12.85 0.68
EC erythrocyte concentrate, FFP fresh frozen plasma, TC thrombocyte concentrate
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association with an increased rate of deep sternal wound
infections [19, 27]. However, neither in crude nor in
propensity score adjusted analysis did our data show any
significant difference in the incidence of deep sternal
wound infections between the total arterial and the
mixed CABG group.
Study restrictions
This study is subject to several limitations that demand
sensible interpretation of the findings. First, this study is
a single-center experience with reduced external validity.
Second, with this retrospective study we were unable to
show causality. This can only be determined through the
design of a randomized controlled trial. Third and final,
even though anticoagulation and antiaggregation scheme
was closely analyzed, we did not assess specific coagula-
tion factor levels and therefore are unable to identify the
impact of secondary hemostasis, clot stability and fibrin-
olysis on perioperative blood consumption.
Conclusions
Reduced rates of red blood cell transfusion were found
in patients who underwent elective, isolated total arterial
CABG for multi-vessel coronary artery disease using
exclusively skeletonized BIMA conduits compared to
mixed CABG using a combination of SIMA and SV con-
duits. Our findings suggest that in respect to periopera-
tive blood loss, the use of BIMA in total arterial CABG
is safe and can also be applied in patients with a low tol-
erance of anemia or patients who will not accept allo-
geneic blood transfusion.
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